Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARINER
NL-OMON41904Phase 3Active, not recruiting
- Sponsor
- Janssen Research & Development
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in venous thromboembolism (VTE) comparing Rivaroxaban with Placebo (2 arms). Primary endpoint: Primary efficacy outcome. Started Feb 2015; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON41904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41904.